A new study has found that people taking Eli Lilly's obesity drug Zepbound lost almost 50% more weight than those using Novo ...

The trends worry health experts, who say the medicines have potential to narrow differences in obesity rates among ...

The Trump administration’s Monday executive order could restructure how Americans buy prescription drugs, pushing them away ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now ...

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an ...

As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity ...

What is the difference between Ozempic, Wegovy and Mounjaro? Curbs will have to be put on which patients are to be eligible for weight loss jabs Mounjaro and Wegovy when they are added to HSE ...

The FDA may begin enforcement actions against pharmacies compounding unauthorized semaglutide after May 22, 2025. Novo Nordisk has filed 111 lawsuits in 32 states to stop the sale of dangerous ...

A federal judge in Texas late Thursday rejected a bid by compounding pharmacies to keep making copies of Ozempic and Wegovy while a legal challenge over the shortage of those drugs unfolds.